Protein expression and methylation of MGMT, a DNA repair gene and their correlation with clinicopathological parameters in invasive ductal carcinoma of the breast
- 29 March 2015
- journal article
- Published by Springer Nature in Tumor Biology
- Vol. 36 (8) , 6485-6496
Abstract
Epigenetic mechanisms such as DNA methylation are being increasingly recognized to play an important role in cancer and may serve as a cancer biomarker. The aim of this study was to evaluate the promoter methylation status of MGMT (O6-methylguanine-DNA methyltransferase) and a possible correlation with the expression of MGMT and standard clinicopathological parameters in invasive ductal breast carcinoma patients (IDC) of Kashmir. Methylation-specific PCR was carried out to investigate the promoter methylation status of MGMT in breast tumors paired with the corresponding normal tissue samples from 128 breast cancer patients. The effect of promoter methylation on protein expression in the primary breast cancer and adjacent normal tissues was evaluated by immunohistochemistry (n = 128) and western blotting (n = 30). The frequency of tumor hypermethylation was 39.8 % and a significant difference in methylation frequency among breast tumors were found (p < 0.001) when compared with the corresponding normal tissue. Immunohistochemical analysis showed no detectable expression of MGMT in 68/128 (53.1 %) tumors. MGMT promoter methylation mediated gene silencing was associated with loss of its protein expression (rs = −0.285, p = 0.001, OR = 3.38, 95 % CI = 1.59–7.17). A significant correlation was seen between loss of MGMT and lymph node involvement (p = 0.030), tumor grade (p < 0.0001), loss of estrogen receptors (ER; p = 0.021) and progesterone receptors (PR) (p = 0.016). Also, MGMT methylation was found to be associated with tumor grade (p = 0.011), tumor stage (p = 0.009), and loss of ER (p = 0.003) and PR receptors (p = 0.009). To our knowledge, our findings, for the first time, in Kashmiri population, indicate that MGMT is aberrantly methylated in breast cancer and promoter hypermethylation could be attributed to silencing of MGMT gene expression in breast cancer. Our data suggests that MGMT promoter hypermethylation could have a potential function as molecular biomarker of breast oncogenesis. Also, based on their predictive value of response to therapy, the immunohistochemical evaluation and interpretation of MGMT may also help in future to establish therapeutic strategies for patients with breast cancer.Keywords
This publication has 45 references indexed in Scilit:
- MGMT and PTEN as potential prognostic markers in breast cancerExperimental and Molecular Pathology, 2012
- Methylation of O 6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patientsBreast Cancer Research and Treatment, 2012
- Association of aberrant DNA methylation with clinicopathological features in breast cancerOncology Reports, 2011
- Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patientsLife Sciences, 2010
- Epigenetic Inactivation of the Potential Tumor Suppressor Gene FOXF1 in Breast CancerCancer Research, 2010
- Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancerBreast Cancer Research, 2010
- Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatmentSeminars in Cancer Biology, 2009
- Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylationNucleic Acids Research, 2007
- Epigenetic Biomarkers and Breast Cancer: Cause for OptimismClinical Cancer Research, 2006
- Detection of Aberrant Methylation of Four Genes in Plasma DNA for the Detection of Breast CancerJournal of Clinical Oncology, 2006